Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label prophylaxis study of subcutaneous C1-esterase inhibitor in Japanese hereditary angioedema
jRCT2080225177Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of C1 esterase inhibitor human in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2), sponsored by CSL Limited. Primary endpoints: Clinical efficacy of CSL830 prophylaxis, Safety of CSL830 prophylaxis and 1 more. Started Apr 2020; status: completed.
02
Drugs
C1 esterase inhibitor human
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on jRCT2080225177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225177.